Taysha Gene Therapies, Inc.

TSHA

CIK 0001806310 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$5M
↑+171.3% +$3Mvs FY2024 (Q4)
Gross Profit
$5M
↑+171.3% +$3Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
65/100
  • Profitability
    0ROIC -42.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 12.23 (above 1.5 = solid)
  • Leverage
    90D/E 0.20 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.04x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +171.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -1347.1% · trend +220.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$362K
investment in PP&E
Stock-based comp (TTM)
$13M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$343M
everything owned
Total liabilities
$96M
everything owed
Stockholders' equity
$247M
shareholder claim
Net debt
$-270M
Net cash position ($270M)

Recent performance · 26 quarters

Revenue↑+171.3% +$3M
$5M
Net Income↓-28.2% -$7M
$-33M
Free Cash Flow
$-250K
Operating Margin↑+568.3pts
-1347.1%

Drill down